Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2022-03-28 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a meeting resolution announcement from the Supervisory Board of Shenzhen Salubris Pharmaceuticals Co., Ltd. It details the approval of various reports and proposals related to the 2021 fiscal year, including the Supervisory Board's work report, the 2021 annual report and its summary, the profit distribution plan, internal control self-evaluation report, and a special report on the use of raised funds. The document also mentions that these reports will be submitted to the 2021 annual shareholders' meeting for approval. The text is an official announcement of the resolutions passed in the Supervisory Board meeting rather than the full annual report itself. The document length is 3744 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, according to the "Menu vs Meal" rule, this document should be classified as a Regulatory Filing (RNS) because it is an official announcement of meeting resolutions and report approvals, not the full annual report or financial statements themselves.
2022-03-28 Chinese
公司章程（2022年3月）
Governance Information Classification · 100% confidence The document is titled as the "章程" (Articles of Association or Company Bylaws) of Shenzhen Salubris Pharmaceuticals Co., Ltd., dated March 2022. It contains detailed provisions about the company's organization, shareholder rights, board structure, share issuance, shareholder meetings, voting procedures, and other governance matters. There is no indication that this is a financial report, earnings release, or any announcement of voting results. Instead, it is a governance document outlining the internal rules and structure of the company. Therefore, the document fits the category of Governance Information (CGR). The document length is substantial (15,000 characters), and it is the full text of the company's articles of association, not an announcement or summary.
2022-03-28 Chinese
2022年第一季度业绩预告
Earnings Release Classification · 95% confidence The document is a quarterly earnings forecast for the first quarter of 2022 by Shenzhen Salubris Pharmaceuticals Co., Ltd. It provides estimated financial results such as revenue, net profit, and earnings per share for the period January 1 to March 31, 2022. It explicitly states that the forecast is unaudited and that detailed financial data will be disclosed in the first quarter report. The document is short (1083 characters) and serves as an earnings preview rather than a full financial report. This matches the definition of an Earnings Release (ER), which is an initial announcement of quarterly financial results with key highlights only. Q1 2022
2022-03-28 Chinese
关于子公司生物医疗增资扩股暨引入战略投资者的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding a capital increase and equity investment in a subsidiary company, Shenzhen Xinlitai Biomedical Engineering Co., Ltd., by introducing strategic investors. It includes comprehensive information about the transaction overview, parties involved, shareholding changes, governance rights, investment terms, and financial data of the subsidiary. The document is not a financial report like an annual or interim report, nor is it a simple announcement of a report publication. It is a formal announcement about a financing activity involving capital structure changes and strategic investment. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length and detail support this classification with high confidence.
2022-03-28 Chinese
关于拟续聘2022年度审计机构的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the proposed reappointment of the audit firm for the fiscal year 2022. It details the audit firm's qualifications, independence, fees, and the approval process by the board and audit committee. It does not contain any actual audit report or financial statements but rather discusses the intention to appoint the auditor and the procedural steps involved. The document length is 4132 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document is best classified as an Audit Report / Information announcement (AR) because it focuses on audit-related information and the appointment of the audit firm, but it is not the audit report itself. However, given the document is primarily an announcement of the auditor appointment and related information, and not the audit report or results, it fits best under AR (Audit Report / Information). FY 2022
2022-03-28 Chinese
内部控制鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as an "内部控制鉴证报告" (Internal Control Assurance Report) and "2021 年度内部控制评价报告" (2021 Internal Control Evaluation Report) issued by an accounting firm (WUYIGE Certified Public Accountants LLP) for Shenzhen Salubris Pharmaceuticals Co., Ltd. It discusses the evaluation of the effectiveness of internal controls related to financial reporting as of December 31, 2021. The document includes detailed descriptions of management responsibilities, auditor responsibilities, internal control limitations, evaluation conclusions, scope, standards for defect recognition, and remediation status. It is a standalone audit-related report focusing on internal control over financial reporting, not a full annual report or interim financial statement. It is not a mere announcement or certification letter but contains substantive audit opinion and evaluation results. This fits the definition of an Audit Report / Information (AR) which includes standalone audit reports and applied accounting principles related to internal controls. The document length (4725 characters) is sufficient to contain detailed audit information rather than a brief announcement. Therefore, the correct classification is AR with high confidence. FY 2021
2022-03-28 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.